Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial

Autor: David I Marks, Amy A Kirkwood, Clare J Rowntree, Melanie Aguiar, Katharine E Bailey, Brendan Beaton, Paul Cahalin, Anna Z Castleton, Laura Clifton-Hadley, Mhairi Copland, Anthony H Goldstone, Richard Kelly, Emma Lawrie, SooWah Lee, Andrew K McMillan, Mary Frances McMullin, Tobias F Menne, Rachel J Mitchell, Anthony V Moorman, Bela Patel, Pip Patrick, Paul Smith, David Taussig, Deborah Yallop, Krisztina Zuborne Alapi, Adele K Fielding

Publikováno v: Marks, D I, Kirkwood, A A, Rowntree, C J, Aguiar, M, Bailey, K E, Beaton, B, Cahalin, P, Castleton, A Z, Clifton-Hadley, L, Copland, M, Goldstone, A H, Kelly, R, Lawrie, E, Lee, S, McMillan, A K, McMullin, M F, Menne, T F, Mitchell, R J, Moorman, A V, Patel, B, Patrick, P, Smith, P, Taussig, D, Yallop, D, Alapi, K Z & Fielding, A K 2022, ' Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial ', The Lancet Haematology, vol. 9, no. 4, pp. e262-e275 . https://doi.org/10.1016/S2352-3026(22)00038-2

BACKGROUND: Treatment for adults with acute lymphoblastic leukaemia requires improvement. UKALL14 was a UK National Cancer Research Institute Adult ALL group study that aimed to determine the benefit of adding the anti-CD20 monoclonal antibody, ritux

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eeb76af476ccd2c9482ebad9b933c975
https://doi.org/10.1016/s2352-3026(22)00038-2

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

Autor: Clare Rowntree, Paul Smith, Pip Patrick, Laura Clifton-Hadley, Rachel J. Mitchell, Bela Wrench, David I. Marks, Amy A Kirkwood, Krisztina Zuborne Alapi, Brendan Beaton, Melanie Aguiar, Tobias Menne, Anthony V. Moorman, Andrew McMillan, Katharine Bailey, Adele K. Fielding, SooWah Lee, Emma Lawrie

Publikováno v: Blood. 134:739-739

UKALL14 (NCT01085617) randomised 655 patients aged 25-65 years with B-precursor ALL, irrespective of Philadelphia chromosome (Ph) status or cell surface CD20 expression to determine if the addition of four doses of rituximab to standard induction che

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::186f4a4b10786534722501e437a27592
https://doi.org/10.1182/blood-2019-123374